期刊
EUROPEAN JOURNAL OF CANCER PREVENTION
卷 22, 期 3, 页码 229-234出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CEJ.0b013e328358761a
关键词
hepatocellular carcinoma; liver cancer; meta-analysis; observational studies; statin(s)
类别
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [10068]
Statins are among the most commonly prescribed drugs used to manage dyslipidemia. Hepatocellular carcinoma is the third leading cause of cancer mortality and its rates have recently been increasing in central and northern Europe and USA. To quantify the association between statin use and risk for HCC, we performed a meta-analysis of published studies. We conducted a MEDLINE search for observational studies reporting the association between exposure to statins and risk for incident liver cancer until March 2012. Fixed-effect and random-effect models were used to estimate summary relative risks (RR) and the corresponding 95% confidence intervals (CIs). Moreover, between-study heterogeneity and publication bias were assessed using adequate statistical tests. Five observational studies (two case-control and three cohort studies) based on 2574 cases of HCC were included. Statin treatment, compared with no treatment, was inversely related to HCC (summary RR=0.58; 95% CI 0.46-0.74). Between-study heterogeneity was significant (P <0.001) and numerically relevant (I-2 = 65%). When only longest statin use was considered, the RR was 0.66 (95% CI 0.55-0.80). Influence analysis on the overall estimate showed that heterogeneity was largely because of one study; when omitting it, the I 2 dropped to 27% (P = 0.240), whereas the summary RR was only marginally modified (RR = 0.52; 95% CI 0.44-0.62). There was no evidence of publication bias. This meta-analysis suggests a favorable effect of statins on HCC, in the absence, however, of a duration-risk relationship. European Journal of Cancer Prevention 22:229-234 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据